References with PepMix™ Peptide Pools - Tumor Associated Antigens



  • Circulating tumor-associated antigen-specific IFN? + 4-1BB + CD8 + T cells as peripheral biomarkers of treatment outcomes in patients with pancreatic cancer
    Murakami et al., Frontiers in Immunology (2024) 
    Products used: PepMix Human (CEA)Human (TERT)Human (WT1/WT33), Human (Mucin-1)
  • Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
    Kelly et al., Nature Medicine (2024) 
  • Multimodal single-cell profiling of T lymphocytes in infection and cancer
    Bieberich, Dissertation (2024)
    Products used: PepMix Human (CEA)Human (MAGEA3)Human (NY-ESO-2)Human (WT1/WT33)
  • Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer
    Dailey et al., Human Vaccines & Immunotherapeutics (2024) - PMID: 38330990
    Products used: Custom PepMix (ESR1), PepMix HIV-1 (GAG) Ultra


  • Prophylactic Vaccination and Intratumoral Boost with HER2-Expressing Oncolytic Herpes Simplex Virus Induces Robust and Persistent Immune Response against HER2-Positive Tumor Cells
    Delwar et al., Vaccines (2023) 
    Product used: PepMix  Human (ErbB2_ECD)
  • Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
    Hall et al., Journal for Immunotherapy of Cancer (2023) - PMID: 37802604
    Product used: Custom PepMix 
  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
    Rojas et al., Nature (2023) - PMID: 37165196
    Product used: Custom PepMix
  • Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation
  • Essawi et al., Molecular Therapy (2023) - PMID: 37273902
    Product used: PepMix S. pyogenes (CAS9)_2 subpools
  • Study of genes involved in HER2-positive breast cancer progression for identification of new therapeutic targets
    Ruzzi, Dissertation (2023)
    Product used: custom PepMix (HER2)
  • Untersuchungen zur Kreuzreaktivität von Cytomegalievirusspezifischen T-Lymphozyten und Tumorassoziierten Antigenen
    Weiß, Dissertation (2023)
    Products used: PepMix™ CMVA (pp65)Human (Mucin-1)Human (NY-ESO-1),  Human (Prame/OIP4) & Human (WT1/WT33)
  • Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor
    Nemeckova et al., Current Oncology (2023) - PMID: 35621629
    Products used: PepMix Human (Prame/OIP4)Human (Mucin-1)


  • Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy
    Bonaventura et al., Immunology (2022)
  • Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy
    Lewicky et al., Pharmaceutics (2022) 
    Products used: PepMix Human (Mucin-1),Human (TERT)Human (CEA)
  • Interdependence of sequential CTL and NK cellcytotoxicityagainst melanomacells
    Friedmann et al., Journal of Physiology (2022) 
    Product used: PepMix Human (Melan-A/MART-1)
  • Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
    Ruzzi et al., Biomedicines (2022) 
  • A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma
    Tan et al., Nature Communications (2022) 
    Product used: PepMix Human (Mucin-1)
  • CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer
    Lee et al., Science Immunology (2022) - PMID: 36026440
    Product used: PepMix Human (NY-ESO-1)
  • Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Tregreduction and effector T cell activation
    van Pul et al., Science Immunology 
    Products used: PepMix Human NY-ESO-1Human Melan-A/MART1CEFT Pool
  • Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer
    Hoyos et al., Therapeutic Advances in Medical Oncology (2022)
    Products used: PepMix Human SurvivinHuman NY-ESO-1Human PRAME/OIP4Human MAGEA4Human SSX2
  • An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
    Fucikova et al., Clinical Cancer Research (2022) - PMID: 35536547
    Products used: PepMix Human (MAGAE3)Human ( MUC1)
  • Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor
    Nemeckova et al., Current Oncology (2022) 
  • Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer
    Matsuzaki et al., Oncoimmunology (2022) - PMID: 35003898
    Products used: PepMix™ Human (Claudin-6)
  • The human CXCR3 chemokine system in early differentiated CD8+ T cell function and solid tumors
    Tino Vollmer, Dissertation (2022)
  • Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens
    Adam S Kibel et al., J Natl Cancer Inst. (2021) - PMID: 33630063 
    Products used: PM-PSA 
  • Phenotype, Specificity and Avidity of Antitumour CD8+ T Cells in Melanoma
    Giacomo Oliveira et al., Nature, (2021) 
  • Targeting Human Acyl-CoA:Cholesterol Acyltransferase as a Dual Viral and T Cell Metabolic Checkpoint
    Nathalie M. Schmidt et al., Nature Communications, (2021) 
    Products used: PM-NYEPM-MAGEA1PM-AFP
  • Design of Peptides With High Affinity Binding to a Monoclonal Antibody as a Basis For Immunotherapy
    Surendra S. Negi et al., Peptides, (2021) 
  • Early disappearance of tumor antigenreactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under antiPD-1 therapy
    Jonas Bochem et al., Journal Immunology, (2021) 
    Products used: PM-MelAPM-NYE
  • Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization
    Anna Przybyla et al., Cancers (Basel) (2021) - PMID: 33435427 
    Products used: PM-GP100PM-NYEPM-TyrPM-MAGEA3PM-MelA
  • Identification of Novel HLA-Restricted Preferentially Expressed Antigen in Melanoma Peptides to Facilitate Off-The-Shelf Tumor-Associated Antigen-Specific T-Cell Therapies
    Maja Stanojevic et al., Cytotherapy, (2021) 
    Products used: PM-OIP4PM-ACTS
  • Activation of Resident Memory T Cells For Cancer Immunotherapy
    David B. Masopust Jr., United States Patent Application 20210000935 (2021) - PMID: n.a.
  • Clinical Effects of Administering Leukemia-Specific Donor T Cells to Patients With AML/MDS Post-Allogeneic Transplant
    Premal Lulla et al., Blood (2020) - PMID: 33270816 
    Products used: PM-SurvivinPM-WT1PM-OIP4PM-NYE
  • Oncolytic Measles Virus Therapy Enhances Tumor Antigen-Specific T-Cell Responses in Patients With Multiple Myeloma
    Nandakumar Packiriswamy et al., Leukemia (2020) - PMID: 32327728 
  • Pre-Transplant Assessment of pp65-Specific CD4 T Cell Responses Identifies CMV-Seropositive Patients Treated With rATG at Risk of Late Onset Infection
    Maria O. López-Oliva et al., Clinical Immunology (2020) - PMID: 31891764
    Products used: PM-IE1PM-PP65-1
  • Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
    Carly M. Bliss et al., Molecular Therapy: Methods & Clinical Development (2019) - PMID: 31934599
  • Evaluation of Newcastle Disease Virus Mediated Dendritic Cell Activation and Cross‐Priming Tumor‐Specific Immune Responses Ex Vivo
    Qi Xu et al., International Journal of Cancer (2019) - PMID: 31584185
  • Natural T Cell Autoreactivity to Melanoma Antigens: Clonally Expanded Melanoma-Antigen Specific CD8 + Memory T Cells Can be Detected in Healthy Humans
    Anna Przybyla et al., Cancer Immunology, Immunotherapy (2019) - PMID: 30783693
  • The Human CD4 T Cell Response Against Mumps Virus Targets a Broadly Recognized Nucleoprotein Epitope
    Jelle de Wit et al., Journal of Virology (2019) - PMID: 30626672
  • Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: a Mouse to Human Translational Study
    Erika J Crosby et al., Clinical Cancer Research (2019) - PMID: 30635338
  • Tel-eVax: a Genetic Vaccine Targeting Telomerase for Treatment of Canine Lymphoma
    Joseph A. Impellizeri et al., Journal of Translational Medicine (2018) - PMID: 30537967
  • Over-Expression of PD-1 Does Not Predict Leukemic Relapse After Allogeneic Stem Cell Transplantation
    Jain et al., Biology of Blood and Marrow Transplantation (2018) - PMID: n.a.
  • A Novel Allogeneic Off-The-Shelf Dendritic Cell Vaccine for Post-Remission Treatment of Elderly Patients with Acute Myeloid Leukemia
    Loosdrecht et al., Cancer Immunol Immunother. (2018) - PMID: 30039426
  • PRAME Peptide‐Specific CD8+ T Cells Represent the Predominant Response Against Leukemia‐Associated Antigens (LAAs) in Healthy Individuals
    Matko et al., European Journal of Immunology (2018) - PMID: 29738081
  • Combined IFN-γ and TNF-α Release Assay for Differentiating Active Tuberculosis from Latent Tuberculosis Infection
    Kim et al., Journal of Infection (2018) - PMID: 29746954
  • Personalized ex vivo Multiple Peptide Enrichment and Detection of T Cells Reactive to Multiple Tumor-associated Antigens in Prostate Cancer Patients
    Taborska et al., Med Oncol. (2017) - PMID: 28866803
  • An Immunogenic Personal Neoantigen Vaccine for Patients with Melanoma
    Ott et al., Nature (2017) - PMID: 28678778
  • Personalized RNA Mutanome Vaccines Mobilize Poly-specific Therapeutic Immunity Against Cancer
    Sahin et al., Nature (2017) - PMID: 28678784
  • Spontaneous CD4+ and CD8+ T Cell Responses Directed Against Cancer Testis Antigens are Present in the Peripheral Blood of Testicular Cancer Patients
    Pearce et al., European Journal of Immunology (2017) - PMID: 28555838
  • Generation of T Cell Effectors Using Tumor Cell-Loaded Dendritic Cells for Adoptive T Cell Therapy
    Vavrova et al., Medical Oncology (2016) - PMID: 27812850
  • A Phase I Study of Recombinant (r) Vaccinia-CEA (6D)-TRICOM and rFowlpox-CEA (6D)-TRICOM Vaccines with GM-CSF and IFN-α-2b in Patients with CEA-Expressing Carcinomas
    Duggan et al., Cancer Immunology, Immunotherapy (2016) - PMID: 27581603
  • Prognostic Impact of High Levels of Circulating Plasmacytoid Dendritic Cells in Breast Cancer
    Bailur et al., Journal of Translational Medicine (2016) - PMID: 27234566
  • Dysfunction of PSA-Specific CD8+ T Cells in Prostate Cancer Patients Correlates with CD38 and Tim-3 Expression
    Japp et al., Cancer Immunol Immunother. (2015) - PMID: 26289091
  • An HPV-E6/E7 Immunotherapy Plus PD-1 Checkpoint Inhibition Results in Tumor Regression and Reduction in PD-L1 Expression
    Rice et al., Cancer Gene Therapy (2015) - PMID: 26337747
  • Survivin-Specific CD4+ T Cells are Decreased in Patients with Survivin-Positive Myeloma
    Locke et al., J Immunother Cancer (2015) - PMID: 25992291
  • A Phase I Trial Combining Decitabine/dendritic Cell Vaccine Targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for Children with Relapsed or Therapy-Refractory Neuroblastoma and Sarcoma
    Krishnadas et al., Cancer Immunol Immunother. (2015) - PMID: 26105625
  • Guidelines For the Automated Evaluation of Elispot Assays
    Janetzki et al., Nature Protocols (2015) - PMID: 26110715
  • Functional Immunological Parameters Associated with Long-term Survival of Patients with Metastatic Melanoma
    Henning Zelba, Dissertation der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen (2015) - PMID: n.a
  • Presence of Circulating Her-2-reactive CD8 + T-Cells is Associated with Lower Frequencies of Myeloid-derived Suppressor Cells and Regulatory T Cells, and Better Survival in Elderly Breast Cancer Patients
    Kini Bailur et al., Breast Cancer Research (2015) - PMID: n.a.
  • STAT3 Signaling Contributes to the High Effector Activities of Interleukin-15-derived Dendritic Cells
    Okada et al., Immunol Cell Biol. (2015) - PMID: 25582338
  • Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
    Weide et al., Clin Cancer Res. (2014) - PMID: 24323899
  • Vaccines Against Antigens Involved in Therapy Resistance and Methods of Using Same
    Lyerly et al., US Patent 20,140,377,261 (2014) - PMID: n.a.
  • Establishment and Maintenance of a PBMC Repository for Functional Cellular Studies in Support of Clinical Vaccine Trials
    Sambor et al., J Immunol Methods. (2014) - PMID: 24787274
  • A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr virus (EBV) Target Antigens: a Phase I Trial in UK Patients with EBV-positive Cancer
    Taylor et al., Clinical Cancer Research (2014) - PMID: 25124688
  • Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma
    Zelba et al., Clin. Cancer Res. (2014) - PMID: 24938524
  • Common Ewing Sarcoma-Associated Antigens Fail to Induce Natural T Cell Responses in Both Patients and Healthy Individuals
    Altvater et al., Cancer Immunol Immunother. (2014) - PMID: 24973179
  • Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
    Weide et al., Cancer Immunology. (2014) - PMID: 24906352
  • Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumor Lysate or Homogenate Combined with Immunomodulating Radiotherapy and/or Preleukapheresis IFN-α in Patients with Metastatic Melanoma: a Randomised “Proof-of principle” Phase II Study
    de Rosa et al., J Transl Med. (2014) - PMID: 25053129
  • Normalizing ELISPOT Responses to T-cell Counts: a Novel Approach for Quantification of HCMV-Specific CD4+ and CD8+ T-Cell Responses in Kidney Transplant Recipients
    Calarota et al., Journal of Clinical Virology (2014) - PMID: n.a.
  • Combination of Interleukin-12 gene Therapy, Metronomic Cyclophosphamide and DNA Cancer Vaccination Directs all Arms of the Immune System Towards Tumor Eradication
    Denies et al., Journal of Controlled Release (2014) - PMID:24887014
  • Decitabine Facilitates Immune Recognition of Sarcoma Cells by Upregulating CT Antigens, MHC molecules, and ICAM-1
    Krishnadas et al., Tumour Biol. (2014) - PMID: 24584817
  • T-Cell Responses after Haematopoietic Stem Cell Transplantation for Aggressive Relapsing-Remitting Multiple Sclerosis
    Burman et al., Immunology (2013) - PMID: 23721329
  • Lentivirus-Induced Dendritic Cells for Immunization Against High-Risk WT1+ Acute Myeloid Leukemia
    Sundarasetty et al., Hum Gene Ther. (2013) - PMID: 23311414
  • Generation of Multi-Leukemia Antigen-Specific T Cells to Enhance the Graft-Versus-Leukemia Effect After Allogeneic Stem Cell Transplant
    Weber et al., Natur Leukemia (2013) - PMID: 23528871
  • Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemia—Implications for Immunotherapy
    Weber et al., Clin. Cancer Res. (2013) - PMID: 23838315
  • Induction of Tumoricidal Function in CD4+ T Cells is Associated with Concomitant Memory and Terminally Differentiated Phenotype
    Hirschhorn-Cymerman et al., J. Exp. Med. (2012) - PMID: 23008334
  • Three Sensitive Assays Do Not Provide Evidence for Circulating HuD-specific T cells in The Blood of Patients with Paraneoplastic Neurological Syndromes with Anti-Hu Antibodies
    de Jonste et al., Neuro Oncology. (2012) - PMID: 22591661
  • Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis
    Weide et al., J. Clin. Oncol. (2012) - PMID: 22529253
  • Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma
    Gerdemann et al., Molecular Therapy (2011) - PMID: 21915103
  • Improving T-Cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
    Cruz et al., Clin. Cancer Res. (2011) - PMID: 21908573
  • Prophylactic Transfer of BCR-ABL–, PR1-, and WT1-Reactive Donor T Cells after T cell–Depleted Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Myeloid Leukemia
    Bornhäuser et al., Blood. (2011) - PMID: 21540460
  • Induction of Complete and Molecular Remissions in Acute Myeloid Leukemia by Wilms’ Tumor 1 Antigen-Targeted Dendritic Cell Vaccination
    Tendeloo et al., PNAS (2010) - PMID: 20631300
  • Antigen-Specific Cytotoxic T Lymphocytes can Target Chemoresistant Side-Population Tumor Cells in Hodgkin’s Lymphoma
    Shafer et al., Leuk Lymphoma. (2010) - PMID: 20367572
  • High-Avidity Cytotoxic-T-lymphocytes Specific for a New Preferentially Expressed antigen of Melanoma (PRAME)-Derived Peptide can Target Leukemic- and Leukemic-precursor Cells
    Quintarelli et al., Blood (2010) - PMID: 21278353
  • MMP11: A Novel Target Antigen for Cancer Immunotherapy
    Peruzzi et al., Clin Cancer Res (2009) - PMID: 19509157
  • Induction of Wilms' Tumor Protein (WT1)-Specific Antitumor Immunity Using a truncated WT1-Expressing Adenovirus Vaccine
    Osada et al., Clin. Cancer Res. (2009) - PMID: 19351755
  • AtPTR1 and AtPTR5 Transport Sipeptides in Planta
    Komarova et al., Plant Physiology Preview (2008) - PMID: 18753286
  • The Wilms' Tumor Antigen is a Novel Target for Human CD4 Regulatory T Cells: Implications for Immunotherapy
    Lehe et al., Cancer Res. (2008) - PMID: 18676860
  • Three-Dimensional MR Mapping of Angiogenesis with 5 1(3)-targeted Theranostic Nanoparticles in the MDA-MB-435 Xenograft Mouse Model
    Schmieder et al., The FASEB Journal (2008) - PMID: 18697838
  • Complete Responses of Relapsed Lymphoma Following Genetic Modification of Tumor-Antigen Presenting Cells and T-lymphocyte Transfer
    Bollard et al., Blood (2007) - PMID: 17609424
  • An MVA Vaccine Overcomes Tolerance to Human p53 in Mice and Humans
    Song et al., Cancer Immunol Immunother (2007) - PMID: 17219151

Check our list of products, click and go.

Get a quote